Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.The European Commission (EC) has provided conditional marketing authorisation for Gilead Sciences to use Veklury (remdesivir) for the treatment of Covid-19.
Gilead noted that the approval comes after a rolling review of supporting data that started in April. The authorisation enables the use of Veklury in adults and adolescents aged 12 years and above with Covid-19-related pneumonia who need supplemental oxygen.
Gilead Sciences chief medical officer Merdad Parsey said: “We appreciate the European Medicines Agency’s rapid review of remdesivir in recognition of the unprecedented nature of this pandemic.